Published online Apr 26, 2020. doi: 10.12998/wjcc.v8.i8.1495
Peer-review started: January 23, 2020
First decision: February 26, 2020
Revised: March 29, 2020
Accepted: April 17, 2020
Article in press: April 17, 2020
Published online: April 26, 2020
Processing time: 78 Days and 20.8 Hours
Anaplastic sarcoma of the kidney (ASK) is a rare and newly recognized renal neoplasm. The tumor usually is extensive and cystic, characterized by pleomorphic spindle cells with marked atypia and associated with multinucleated cells. To date, only 27 cases have been reported in the literature. The authors present an additional case and summarize the relevant knowledge in the literature.
A 27-year-old previously healthy woman presented with a palpable mass over the abdomen and right flank soreness for one year. After the computed tomography study, the patient underwent right radical nephrectomy obtaining a 1680-g tumor with a size of 18.4 cm × 14.5 cm × 11 cm. The tumor is chiefly composed of anaplastic spindle cells with marked nuclear atypia admixed with multinucleated cells. Immunohistochemical evaluation of tumor cells exhibited diffuse positivity for CD56, p53, and vimentin, and focally positive for desmin. The diagnosis of ASK was established. Unfortunately, a local tumor recurrence followed by a distant metastasis developed within months. The patient died 26 months after the initial surgery. Comparing to the previously 27 cases of ASK, the current case had a relatively worse prognosis, which might be potentially associated with older patient age, larger tumor size, and the lack of en-bloc resection of adjacent organs during the initial radical nephrectomy.
This case points out the featured pathological findings for diagnosing ASK and suggests more aggressive management for patients with ASK.
Core tip: The current case report points out the crucial features to differentiate the rare tumor, anaplastic sarcoma of the kidney (ASK), from other renal malignancies. Besides, the authors summarized the demographic, clinical, and prognostic information of the 28 ASK cases reported in the literature. Based on the lethal outcome in a 5-year old patient and two patients with stage 1 of the disease at presentation, we suggest that all patients with ASK should receive radical nephrectomy, en bloc resection of adjacent organs, chemotherapy, and long-term close follow-up. Further experience is essential to modify this approach in the future.